ClinicalTrials.gov
ClinicalTrials.gov Menu

Blood Flow MRI for Monitoring Brain Tumors (Glioma)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01538264
Recruitment Status : Recruiting
First Posted : February 24, 2012
Last Update Posted : March 21, 2018
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
David Alsop, Beth Israel Deaconess Medical Center

Brief Summary:
The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors. This technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard MRI scanner.

Condition or disease
Brain Tumors

Detailed Description:

Our goals are:

  1. To compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. This will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors.
  2. To compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. This choline concentration can be measured with another MRI technique. This information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary.
  3. To determine the reproducibility of blood flow measurements in tumors. This is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity.
  4. To monitor changes in blood flow after initial treatment. Since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.

Study Type : Observational
Estimated Enrollment : 125 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Blood Flow MRI for Monitoring of Glioma Angiogenesis
Study Start Date : June 2006
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Brain Tumors





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All subjects will be brain tumor patients recruited through the Brain Tumor Center at the Beth Israel Deaconess Medical Center.
Criteria

Inclusion Criteria:

  • diagnosed with or are suspected of having a glioma

Exclusion Criteria:

  • contraindications to MRI which may include the following

    1. Pacemaker
    2. MRI incompatible metal implant
    3. Recently implanted vascular clip
    4. History of claustrophobia
    5. Metal fragment within the eye

Subjects who have received nonstandard therapy may be excluded if the therapy might alter tumor blood flow or other imaging characteristic.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538264


Contacts
Contact: Teresa Russell, BS trussell@bidmc.harvard.edu
Contact: Grace Vincent, BA gvincent@bidmc.harvard.edu

Locations
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Teresa Russell, BS       trussell@bidmc.harvard.edu   
Contact: Grace Vincent, BA       gvincent@bidmc.harvard.edu   
Principal Investigator: David C Alsop, PhD         
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: David C Alsop, PhD Beth Israel Deaconess Medical Center

Responsible Party: David Alsop, Professor of Radiology, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier: NCT01538264     History of Changes
Other Study ID Numbers: 2006P000116
R01CA115745-05 ( U.S. NIH Grant/Contract )
First Posted: February 24, 2012    Key Record Dates
Last Update Posted: March 21, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Neoplasms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases